Cereno Scientific participates at the 19th Global CVCT Forum 2022 discussing clinical trials in cardiovascular disease with top thought leaders
Cereno Scientific (XSAT: CRNO B) today announced the company will participate at the 19th Global CVCT Forum 2022 on December 1-3, 2022, in Washington D.C., US. The Global Cardiovascular Clinical Trialists (CVCT) Forum brings together the top thought leaders in cardiovascular disease and is co-chaired by Dr Bertram Pitt and Dr Faiez Zannad, both part of Cereno’s Scientific Advisory Board. Cereno’s Chief Medical Officer (CMO), Dr Björn Dahlöf, is invited to speak and participate in several program sessions providing an industry perspective on significant topics such as patient benefit, clinical trial designs, and PAH-specific drug development.
“We are excited to also this year be an active part of the Global CVCT Forum 2022. As a biotech company focused on cardiovascular disease, we are in the thick of clinical development and have both learnings to share but also knowledge to gain that may contribute to our clinical development plans. It is not only an honor to be invited to participate in the program, but an important arena to continue to build relationships with academia, regulatory representatives, investigators, patients as well as sharing the stage with industry pharma majors,” said Sten R. Sörensen, CEO of Cereno Scientific.
The Global Cardiovascular Clinical Trialists (CVCT) Forum is a unique annual educational forum aimed at discussing the latest and most critical cardiovascular, cardiorenal and cardiometabolic trials. This invitation-only event brings together around 300 handpicked of the global key thought leaders and top executives of large pharmaceutical companies, regulatory authorities, and promising biotech companies. Cereno’s CMO Dr Björn Dahlöf will participate in the following program sessions:
- The CVCT Forum multi-stakeholder moderated debate: Solving the equation of maximizing the net benefit of anti-thrombotic therapy
- Participating in a moderated debate
- Thrombosis trials: Integrating benefit and risk in clinical trials
- Providing an industry viewpoint
- Pulmonary arterial hypertension trials (part 1): New pathways and new biotargets investigated in new trials
- Presenting the session ‘Histone Deacetylase inhibition (HDACi) for PAH?’
- The CVCT Forum multi-stakeholder moderated debate: Do we need new modes of evidence generation for newer drugs?
- Participating in a moderated debate
- The CVCT Forum multi-stakeholder moderated debate: How to adapt trial design and endpoints in non-PAH PH
- Participating in a moderated debate
More information about the program and attendees at the CVCT Forum 2022 is available on their website, https://www.globalcvctforum.com/scientific-program-2022.
For further information, please contact:
Hans Naess, interim CFO
Phone: +46 793 40 79 00
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About the CVCT Forum
The Global Cardiovascular Clinical Trialists (CVCT) Forum is a unique annual educational forum aimed at discussing the latest and most critical cardiovascular, cardiorenal and cardiometabolic trials. Their annual meetings are invitation-only bringing together around 300 global key thought leaders and top executives of large pharmaceutical companies, regulatory authorities, and promising biotech companies. The organization plays a significant role in the field of cardiovascular disease by giving out summaries and guidance on clinical trials.
Recently, a whitepaper was published in the top-tier medical journal the Lancet drawing conclusions from two discussion sessions at last year’s CVCT Forum 2021 wherein Cereno’s CMO Dr Björn Dahlöf participated. The article is titled ‘The evolving landscape of pulmonary arterial hypertension clinical trials with the outcome’ and includes suggestions for innovative study design in PAH. Find article here: Weatherald J, Boucly A, Peters A, et al. The evolving landscape of pulmonary arterial hypertension clinical trials. Lancet 2022; 400: 1984–1898.
About Cereno Scientific AB
Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.